Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, announced receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product, SBP-101, being developed for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in […]